- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia (AML)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1745KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 695KB)
Gemtuzumab ozogamicin – March 2021
Gemtuzumab ozogamicin: Powder for injection 5 mg; Mylotarg®
Last updated
16 July 2021